Design, synthesis and anti-tumor activity of combretastatin A-4 derivatives

WU Wenping; LI Sisi; MA Cheng

doi:10.11665/j.issn.1000-5048.20220304

Journal of China Pharmaceutical University > 2022 > 53(3): 278-285. > DOI: 10.11665/j.issn.1000-5048.20220304

WU Wenping, LI Sisi, MA Cheng. Design, synthesis and anti-tumor activity of combretastatin A-4 derivatives[J]. Journal of China Pharmaceutical University, 2022, 53(3): 278-285. DOI: 10.11665/j.issn.1000-5048.20220304

Citation:

PDF (1413 KB)

Design, synthesis and anti-tumor activity of combretastatin A-4 derivatives

College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China

Funds: The study was supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region (No.2019D01C28), and the Project of Xinjiang Key Laboratory of Active Components of Natural Medicine and Drug Release Technology (No.XJDX1713)

More Information

Received Date: March 10, 2022
Revised Date: April 25, 2022

Graphical Abstract

Abstract

Abstract

Based on the structure of combretastatin A-4 (CA-4), a microtubulin inhibitor, eight novel compounds were designed and synthesized by introducing different substituents into the benzimidazole backbone which substituted B ring of CA-4, and the structures were characterized by NMR and HRMS. Proliferation inhibition of six tumor cells including A549, HepG2, HCT-116, MCF-7, PC-3 and Siha was measured by MTT method.The effect of active compound on cell migration was evaluated by scratch test.Molecular docking technique was applied to investigate the interaction between the most active compound with the tubulin and PI3K kinases respectively.Compound 4e showed prominent inhibition against six strains of tumor cells, especially with the strongest inhibitory effect on Siha cells (IC₅₀ = 12.18 ± 1.17 μmol/L).Moreover, compound 4e could effectively inhibit cell migration, which deserves further study.Molecular docking study showed that the binding energy to the tubulin of compound 4e was stronger than that of CA-4, and the affinity with PI3Ks displayed that the PI3Kδ subtype kinase was the strongest; its binding energy was -37.2 kJ/mol.This study lays a foundation for the development of anti-tumor drug based on PI3K and microtubulin.
- combretastatinA-4,
- tubulin,
- phosphoinositide 3-kinase,
- synthesis,
- anti-tumor

FullText(HTML)

References (26)

References

[1]	. CA Cancer J Clin，2021，71（3）：209-249.
[2]	Figueroa-Magalh?es MC，Jelovac D，Connolly RM，et al. Treatment of HER2-positive breast cancer［J］. Breast，2014，23（2）：128-136.
[3]	Sun YT，Jiang LQ，Wen T，et al. Trends in the research into immune checkpoint blockade by anti-PD1/PDL1 antibodies in cancer immunotherapy：a bibliometric study［J］. Front Pharmacol，2021，12：670900.
[4]	Cushing TD，Metz DP，Whittington DA，et al. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases［J］. J Med Chem，2012，55（20）：8559-8581.
[5]	Joshi MC，Kumar K，Kumar V. Potent phosphatidylinositol 3-kinase inhibitors and their biology［J］. Curr Drug Discov Technol，2014，11（2）：113-126.
[6]	Huang QX，Gao S，Zhao DQ，et al. Review of ginsenosides targeting mitochondrial function to treat multiple disorders：current status and perspectives［J］. J Ginseng Res，2021，45（3）：371-379.
[7]	Huang TT，Brill E，Nair JR，et al. Targeting the PI3K/mTOR pathway augments CHK₁ inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cancer［J］. Cancer Res，2020，80（23）：5380-5392.
[8]	Zhu SR，Liu XL，Xue M，et al. 20（S）-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB₄ cells via Akt/Ba_x/caspase9 and TNF-α/caspase8 signaling cascades［J］. J Ginseng Res，2021，45（2）：295-304.
[9]	Herschbein L，Liesveld JL. Dueling for dual inhibition：means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML［J］. Blood Rev，2018，32（3）：235-248.
[10]	Vlahos CJ，Matter WF，Hui KY，et al. A specific inhibitor of phosphatidylinositol 3-kinase，2-（4-morpholinyl）-8-phenyl-4H-1-benzopyran-4-one （LY294002）［J］. J Biol Chem，1994，269（7）：5241-5248.
[11]	Walker EH，Pacold ME，Perisic O，et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin，LY294002，quercetin，myricetin，and staurosporine［J］. Mol Cell，2000，6（4）：909-919.
[12]	Bell K，Sunose M，Ellard K，et al. SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors［J］. Bioorg Med Chem Lett，2012，22（16）：5257-5263.
[13]	Lv XY，Zhang YM，Liu L. Research progress of PI3K inhibitors combined with anti-tumor drugs［J］. Food and Drug（食品与药品），2020，22（2）：158-167.
[14]	Bohnacker T，Prota AE，Beaufils F，et al. Deconvolution of Buparlisib''s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention［J］. Nat Commun，2017，8：14683.
[15]	McKay RR，de Velasco G，Werner L，et al. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies［J］. Cancer，2016，122（15）：2389-2398.
[16]	Al-Hamashi AA，Koranne R，Dlamini S，et al. A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics［J］. Bioorg Chem，2021，116：105297.
[17]	Wang Z，Guan Q，Zhang XJ. Advances in combretastatin A-4 analogues of tubulin colchicine binding site inhibitors［J］. J Shenyang Pharm Univ（沈阳药科大学学报），2019，36（9）：844-852.
[18]	Liu RL，Huang MX，Zhang S，et al. Design，synthesis and bioevaluation of 6-aryl-1-（3，4，5-trimethoxyphenyl）-1H-benzo［d］imidazoles as tubulin polymerization inhibitors［J］. Eur J Med Chem，2021，226：113826.
[19]	Pettit GR，Singh SB，Hamel E，et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4［J］. Experientia，1989，45（2）：209-211.
[20]	Hagras M，El Deeb MA，Elzahabi HSA，et al. Discovery of new quinolines as potent colchicine binding site inhibitors：design，synthesis，docking studies，and anti-proliferative evaluation［J］. J Enzyme Inhib Med Chem，2021，36（1）：640-658.
[21]	Ren YC，Ruan Y，Cheng BB，et al. Design，synthesis and biological evaluation of novel acridine and quinoline derivatives as tubulin polymerization inhibitors with anticancer activities［J］. Bioorg Med Chem，2021，46：116376.
[22]	Fan Y，Luo Y，Ma C. Synthesis and cytotoxic evaluation of combretastatin A-4 analogues of benzo［b］furans［J］. Monatsh Chem，2017，148：1823-1832.
[23]	Gao YT，Ma C，Feng XZ，et al. BF12，a novel benzofuran，exhibits antitumor activity by inhibiting microtubules and the PI3K/Akt/mTOR signaling pathway in human cervical cancer cells［J］. Chem Biodivers，2020，17（3）：e1900622.
[24]	Xiaohelaiti HMT，Gao YT，Ma C，et al. Design，synthesis and antitumor activity screening of 2-aryl benzimidazoles［J］. Northwest Pharm J（西北药学杂志），2020，35（2）：249-254.
[25]	Gilfillan L，Blair A，Morris BJ，et al. Synthesis and biological evaluation of novel 2，3-dihydro-1H-1，5-benzodiazepin-2-ones； potential imaging agents of the metabotropic glutamate 2 receptor［J］. Med Chem Commun，2013，4（7）：1118-1123.
[26]	Won DI，Lee JS，Ji JM，et al. Highly robust hybrid photocatalyst for carbon dioxide reduction：tuning and optimization of catalytic activities of dye/TiO₂/Re（I） organic-inorganic ternary systems［J］. J Am Chem Soc，2015，137（42）：13679-13690.

[1]	ZHANG Xueling, LI Na, CHEN Li. Progress of research on celastrol derivatives as anti-tumor agents[J]. Journal of China Pharmaceutical University, 2024, 55(6): 826-836. DOI: 10.11665/j.issn.1000-5048.2023041802
[2]	LIANG Guangping, YANG Jun, WU Yunqiu, WAN Luping, RUAN Lijun, SONG Zhijun. Synthesis and anti-tumor activity of Z-Gly-Pro-OH-podophyllotoxin derivatives[J]. Journal of China Pharmaceutical University, 2022, 53(1): 32-40. DOI: 10.11665/j.issn.1000-5048.20220105
[3]	ZHANG Danfeng, JIAO Yu, LIU Yong, ZHANG Yanmin, ZHANG Zhimin, LU Tao. Progress of small molecule anti-tumor covalent drugs[J]. Journal of China Pharmaceutical University, 2017, 48(1): 1-7. DOI: 10.11665/j.issn.1000-5048.20170101
[4]	MAO Zewei, WAN Chunping, JIANG Yuan, GUO Wenlian, RAO Gaoxiong. Synthesis and anti-tumor activity in vitro of N-hetercycle substituted benzofuran derivatives[J]. Journal of China Pharmaceutical University, 2015, 46(1): 58-61. DOI: 10.11665/j.issn.1000-5048.20150106
[5]	HE Liqin, WU Yaxian, FU Li, WANG Xiaoshan, ZHANG Yihua. Synthesis and biological evaluation of aminoalcohol gambogate as anti-tumor agents[J]. Journal of China Pharmaceutical University, 2013, 44(5): 394-400. DOI: 10.11665/j.issn.1000-5048.20130503
[6]	CHU Xiaojing, ZHANG Ying, QIAO Chunhua, AO Guizhen, YANG Shengwei, DONG Yan. Synthesis and anti-tumor activity of rhodanine derivatives[J]. Journal of China Pharmaceutical University, 2013, 44(2): 113-116. DOI: 10.11665/j.issn.1000-5048.20130203
[7]	ZHU Zi-fei, TANG Jia, WANG Ting-ting, CHEN Li. Synthesis and anti-tumor activity of novel betulinic acid derivatives[J]. Journal of China Pharmaceutical University, 2012, 43(5): 395-400.
[8]	Transcription factors as new targets for cancer therapy[J]. Journal of China Pharmaceutical University, 2010, 41(2): 97-103.
[9]	ZHAO Hao-Ru, LI Rui, LIN Yi-Ning, CHENG Nai-Lin. Influence of Extraction Process of Hedyotis diffusa on Anti-tumor Activity[J]. Journal of China Pharmaceutical University, 2002, (6).
[10]	Study on the Anti-tumor Effects of Polysaccharide (PSP) from the Spirulina Platensis in Mice[J]. Journal of China Pharmaceutical University, 2000, (6): 58-61.

Cited By

Cited by

Periodical cited type(1)

李斯思，陈俊杰，吴文平，朵特娜，马成. 苯并咪唑类化合物抗宫颈癌活性的3D-QSAR及分子对接研究. 中国药物化学杂志. 2024(02): 81-92 .

Other cited types(0)

Get Citation

PDF

XML

Article views (207) PDF downloads (351) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Design, synthesis and anti-tumor activity of combretastatin A-4 derivatives

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Design, synthesis and anti-tumor activity of combretastatin A-4 derivatives

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content